SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Suven Life Sciences reports Profit after tax of Rs -109.83 Mln, in the September 2021 quarter

25 Oct 2021 Evaluate
The Sales for the quarter ended September 2021 of Rs. 11.84 million declined by -86.82% from Rs. 89.80 millions.The Net Loss for the quarter ended September 2021 is Rs. -109.83 millions as compared to Net Loss of Rs. -19.00 millions of corresponding quarter ended September 2020 Operating profit Margin for the quarter ended September 2021 further decreased to -97.99% as compared to -15.67% of corresponding quarter ended September 2020


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202109 202009 % Var 202109 202009 % Var 202103 202003 % Var
Sales 11.84 89.80 -86.82 31.90 104.09 -69.35 134.78 144.15 -6.50
Other Income 5.03 22.77 -77.91 50.58 48.06 5.24 77.54 140.36 -44.76
PBIDT -97.99 -15.67 525.34 -171.05 -68.52 149.64 -227.93 -212.80 7.11
Interest 1.50 2.53 -40.71 3.03 4.48 -32.37 8.15 4.87 67.35
PBDT -99.49 -18.20 446.65 -174.08 -73.00 138.47 -236.08 -217.67 8.46
Depreciation 10.34 10.75 -3.81 20.68 21.40 -3.36 43.46 41.69 4.25
PBT -109.83 -28.95 279.38 -194.76 -94.40 106.31 -279.54 -259.36 7.78
TAX 0.00 -9.95 0.00 0.00 -34.62 0.00 -53.23 -121.83 -56.31
Deferred Tax 0.00 -9.95 0.00 0.00 -34.62 0.00 -53.23 -141.55 -62.39
PAT -109.83 -19.00 478.05 -194.76 -59.78 225.79 -226.31 -137.53 64.55
Equity 127.28 127.28 0.00 127.28 127.28 0.00 127.28 127.28 0.00
PBIDTM(%) -827.62 -17.45 4642.82 -536.21 -65.83 714.56 -169.11 -147.62 14.56

Suven Life Sciences Share Price

195.90 -0.10 (-0.05%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×